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Metabolic Syndrome and 10-Year Cardiovascular Disease
Risk in the Hoorn Study
Jacqueline M. Dekker, PhD; Cynthia Girman, PhD; Thomas Rhodes, MSPH; Giel Nijpels, MD, PhD;
Coen D.A. Stehouwer, MD, PhD; Lex M. Bouter, PhD; Robert J. Heine, MD, PhD
Background—Different definitions of the metabolic syndrome have been proposed. Their value in a clinical setting to
assess cardiovascular disease (CVD) risk is still unclear. We compared the definitions proposed by the National
Cholesterol Education Program Adult Treatment Panel III (NCEP), World Health Organization (WHO), European
Group for the Study of Insulin Resistance (EGIR), and American College of Endocrinology (ACE) with respect to the
prevalence of the metabolic syndrome and the association with 10-year risk of fatal and nonfatal CVD.
Methods and Results—The Hoorn Study is a population-based cohort study. The present study population comprised 615
men and 749 women aged 50 to 75 years and without diabetes or a history of CVD at baseline in 1989 to 1990. The
prevalence of the metabolic syndrome at baseline ranged from 17% to 32%. The NCEP definition was associated with
about a 2-fold increase in age-adjusted risk of fatal CVD in men and nonfatal CVD in women. For the WHO, EGIR,
and ACE definitions, these hazard ratios were slightly lower. Risk increased with the number of risk factors. Elevated
insulin levels were more prevalent in subjects with multiple risk factors, but metabolic syndrome definitions including
elevated insulin level were not more strongly associated with risk.
Conclusions—The metabolic syndrome, however defined, is associated with an approximate 2-fold increased risk of incident
cardiovascular morbidity and mortality in a European population. In clinical practice, a more informative assessment can be
obtained by taking into account the number of individual risk factors. (Circulation. 2005;112:666-673.)
Key Words: risk factors  insulin resistance  cardiovascular diseases  prognosis  glucose
The global increase in overweight and obesity has beenshown to result in a dramatic increase of type 2 diabetes
and is expected to lead to an increase in cardiovascular
disease (CVD) as well.1 Obesity and the subsequent cluster-
ing of insulin resistance–related CVD risk factors result in a
state of high risk for diabetes and CVD.2,3 To enable
international comparison of studies, the World Health Orga-
nization (WHO) in 1999 published a working definition of
the metabolic syndrome.4 Alternative definitions have subse-
quently been proposed by the European Group for the Study
of Insulin Resistance (EGIR),5 the Adult Treatment Panel III
of the National Cholesterol Education Program (NCEP),6 and
the American College of Endocrinology (ACE).7 All defini-
tions include a measure of blood pressure, triglycerides, HDL
cholesterol, and fasting glucose. They differ with respect to
the selection of cutoff points and a measure of obesity. In
contrast to the WHO and EGIR definitions, in which the
presence of hyperinsulinemia as an indicator of insulin
resistance is the starting point, the NCEP definition is based
on the number of abnormalities only, whereas the ACE
definition considers the number of abnormalities in selected
subjects with high risk of insulin resistance.
So far, there is limited information about the agreement
between these different definitions and about the magnitude
of their association with fatal and nonfatal CVD. Several
population studies have reported an approximately 2-fold
increased risk of CVD in the presence of the metabolic
syndrome using one of the proposed definitions.8–17 No
previous study reported the results for fatal and nonfatal CVD
separately, nor compared all 4 proposed definitions for men
and women. Here, we present the agreement of the 4
definitions of the metabolic syndrome in Dutch men and
women and their predictive value for total mortality and for
fatal and nonfatal CVD.
Methods
Population
The Hoorn Study is a Dutch cohort study of diabetes and diabetes
complications in the general population that began in 1989. The
cohort and baseline measurements have been described in detail
previously.18 Briefly, a random selection of 3553 men and women 50
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to 75 years of age was taken from the population register. A total of
2540 (71.5%) agreed to participate, and after exclusion of 56
nonwhite participants, the Hoorn Study population consisted of 2484
men and women. For the present study, we excluded 612 subjects
with missing information on morbidity during follow-up (because
they did not give written permission to access their hospital files or
moved out of Hoorn) and 72 subjects with missing information on
metabolic syndrome variables. Another 90 patients with known
diabetes (based on treatment with glucose-lowering medication or
diet), 120 subjects with diabetic fasting plasma glucose values
(7.0 mmol/L, American Diabetes Association 1997), and 470
subjects with self-reported history of CVD were excluded for
analysis of the predictive value of the metabolic syndrome, which
left 615 men and 749 women. All participants gave their written
informed consent. The study was approved by the Ethics Committee
of the VU University Medical Center.
Baseline Examination
At the baseline medical examination, a blood sample was taken from
all participants after overnight fasting. Weight and height were
measured, and body mass index (BMI) was calculated as the ratio of
weight and height squared. Blood pressure was measured twice on
the right arm with a random-zero sphygmomanometer (Hawksley-
Gelman Ltd). A standard 75-g oral glucose tolerance test was
performed in all subjects, except those using glucose-lowering
medication. Plasma glucose was determined with a glucose dehy-
drogenase method (Merck). Fasting insulin was determined with an
insulin-specific double-antibody radioimmunoassay (antibody:
Linco SP21). Fasting triglycerides and total and HDL cholesterol
were determined by enzymatic techniques (Boehringer-Mannheim).
LDL cholesterol was estimated with the Friedewald formula, except
in subjects with triglycerides8.0 mmol/L. Information about use of
medication, including antihypertensive medication, smoking status
(nonsmokers, ex-smokers, and current smokers), and history of CVD
(assessed by Rose Questionnaire) were determined by self-
administered questionnaire.
Follow-Up
The cohort is being followed up with respect to morbidity and
mortality. Vital status is obtained from the population register of the
city of Hoorn. Information on morbidity and mortality is obtained
from the medical records of the general practitioners and the local
hospital. Causes of death were coded according to the International
Classification of Diseases, Injuries and Causes of Death, ninth
revision (ICD-9).
CVD was defined as documented angina pectoris (chest pain
followed by coronary artery bypass surgery or angioplasty, or in the
presence of 50% stenosis, or ECG changes or positive exercise
test), myocardial infarction (in the presence of at least 2 of the
following: typical pain, elevated enzymes, or ECG changes), con-
gestive heart failure (in the presence of at least 2 of the following:
shortness of breath, cardiomegaly, or dilated neck veins, or 1 of the
former in the presence of edema or tachycardia), stroke or transient
ischemic attack (sudden onset of symptoms, neurological symptoms,
or change of consciousness), peripheral disease (by procedure, or
typical pain accompanied by stenosis, ankle-arm blood pressure ratio
0.90, or positive vascular stress test). In fatal cases, CVD was
defined with ICD codes 390 to 459 (diseases of the circulatory
system) or 798 (sudden death, cause unknown), because sudden
death in general is of CVD origin. Data on nonfatal outcomes were
complete until 2000. Until January 2000, 271 subjects died, 309 had
at least 1 nonfatal CVD event, and 383 had at least 1 fatal and/or
nonfatal CVD events. Follow-up time was calculated as the time
between the date of baseline physical examination and the date of the
first event or January 1, 2000.
Metabolic Syndrome Definitions
Table 1 summarizes the 4 criteria. The NCEP definition6 considers
the syndrome to be present with at least 3 of the following: elevated
fasting glucose, elevated triglycerides, low HDL, high blood pres-
sure, or large waist circumference. The WHO definition4 defines the
syndrome with insulin resistance in the upper quartile of the
population and/or impaired glucose regulation in combination with
at least 2 of dyslipidemia (elevated triglycerides or low HDL), high
blood pressure, or obesity (high waist-to-hip ratio or high BMI).
Because information on the presence of microalbuminuria is not
generally available in clinical practice and was available only for a
subset of the present study population, this component was not used
in the present study, which followed the WHO modified definition in
a prior study.16 Insulin resistance was estimated by fasting insulin
(75th percentile: 94.95 pmol/L) or by the HOMA equation19 (ho-
meostasis model assessment of insulin resistancefasting insulin
[IU/L]fasting glucose [mmol/L]/22.5; 75th percentile: 3.91). The
TABLE 1. Metabolic Syndrome Definitions of NCEP, WHO, EGIR, and ACE
NCEP WHO EGIR ACE
Required    Required: Insulin in top 25%;
glucose 6.1 mmol/L 110
mg/dL; 2-hour glucose
7.8 mmol/L 140 mg/dL
Required: Insulin in top 25% High risk*; BMI 25 kg/m2 or
waist 102 cm (men) or 88
cm (women)
No. of abnormalities >3 of: And >2 of: And >2 of: And >2 of:
Glucose 6.1 mmol/L 110 mg/dL 6.1 mmol/L 110 mg/dL 6.1 mmol/L 110 mg/dL;
2-hour glucose 7.8 mmol/L
140 mg/dL
HDL cholesterol 1.0 mmol/L 40 mg/dL
(men); 1.3 mmol/L 50
mg/dL (women)
0.9 mmol/L 35 mg/dL
(men); 1.0 mmol/L 40
mg/dL (women)
1.0 mmol/L 40 mg/dL 1.0 mmol/L 40 mg/dL
(men); 1.3 mmol/L 50
mg/dL (women)
or or
Triglycerides 1.7 mmol/L 150 mg/dL 1.7 mmol/L 150 mg/dL 2.0 mmol/L 180 mg/dL 1.7 mmol/L 150 mg/dL
Obesity Waist 102 cm (men) or 88
cm (women)
Waist/hip ratio 0.9 (men) or
0.85 (women); BMI 30
kg/m2
Waist 94 cm (men) or 80
cm (women)
Hypertension 130/85 mm Hg 140/90 mm Hg 140/90 mm Hg 130/85 mm Hg
*For the ACE definition, high risk of being insulin resistant is indicated by the presence of at least 1 of the following: diagnosis of CVD, hypertension, polycystic
ovary syndrome, nonalcoholic fatty liver disease, or acanthosis nigricans; family history of type 2 diabetes, hypertension, or CVD; history of gestational diabetes or
glucose intolerance; nonwhite ethnicity; sedentary lifestyle; BMI 25 kg/m2 or waist circumference 94 cm for men and 80 cm for women; and age40 years.
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EGIR definition5 considers the syndrome to be present in subjects
with fasting insulin in the upper quartile of the population distribu-
tion, in the presence of at least 2 of these risk factors: elevated fasting
glucose, dyslipidemia (elevated triglycerides or low HDL), high
blood pressure, or high waist circumference. The ACE definition7
considers the syndrome to be present with 2 or more abnormalities
(of elevated fasting or postload glucose, elevated triglycerides, low
HDL, or high blood pressure) in subjects who have high risk of being
insulin resistant (see Table 1 for definition). In the present study, all
subjects were older than 40 years, and thus, all were part of the
high-risk group. Because the oral glucose tolerance is not performed
in usual clinical care, the information on the 2-hour glucose values
was not used for the WHO and ACE definitions in the present study,
except for additional analyses.
Statistical Analyses
The agreement between the definitions was determined by the kappa
statistic ().20 The level of agreement is considered poor with
0.20, fair with  0.21 to 0.40, moderate with 0.41 to 0.60,
substantial with 0.61 to 0.80, and very good with 0.80.20 The
age-adjusted hazard ratios of the alternative definitions of the
syndrome and their components with nonfatal CVD morbidity, CVD
morbidity and mortality combined, and CVD mortality and total
mortality were estimated with Cox proportional hazards analysis. To
study the additional value of the metabolic syndrome definitions over
risk factors that are already taken into account in usual clinical
practice, we also adjusted for current smoking and LDL cholesterol
and separately for 10-year risk categories (10% to 20%, and 20%
relative to 10%) as estimated by the Framingham score.21 Further-
more, we studied the number of abnormalities in relation to the
proportion of subjects with hyperinsulinemia and the hazard ratio of
increasing number of abnormalities for risk of fatal and nonfatal
CVD.
Results
Baseline characteristics in subjects with and without the
metabolic syndrome according to the NCEP definition are
shown in Table 2. For both men and women, approximately
half of the subjects with the syndrome had insulin levels in
the upper quartile of the population, and 15% of the women
and 21% of the men without the syndrome reached these
levels. The prevalence of the metabolic syndrome according
to the NCEP definition was 19% in men and 26% in women.
For the WHO, EGIR, and ACE definitions, the prevalences
were 32%, 19%, and 41%, respectively, in men, and 26%,
17%, and 35%, respectively, in women. The agreement
between the definitions ranged from a  of 0.28 between
EGIR and ACE definitions in men (fair agreement) to 0.78
(substantial agreement) between NCEP and ACE definitions
in women (Table 3).
The NCEP definition was associated with an approxi-
mately 2-fold risk of all end points in men and of nonfatal
CVD in women, after adjustment for age only (Table 4). The
hazard ratios of the WHO, EGIR, and ACE definitions for all
end points were just slightly lower. In men, the highest hazard
ratio of the constituent risk factors and metabolic syndrome
definitions were generally observed for fatal CVD, whereas
in women, the associations were stronger for nonfatal CVD.
The estimated risk for metabolic syndrome was not greater
than for the individual components of the syndrome. Adjust-
ment for current smoking and LDL cholesterol attenuated the
associations with fatal and nonfatal CVD combined only for
ACE in men and NCEP and ACE in women (Table 5). After
adjustment for the 10-year coronary heart disease risk, as
estimated with the Framingham risk score, the hazard ratios
associated with the WHO and EGIR definitions did not
change markedly. The hazard ratio of the NCEP and ACE
metabolic syndrome definitions were reduced to 1.6 and 1.1
in men, and in women, the hazard ratios were reduced to 1.2
to 1.3 and not statistically significant (Table 5).
TABLE 2. Baseline Characteristics in 615 Men and 749 Women Without Diabetes or Prevalent
CVD, According to the Presence of the NCEP Metabolic Syndrome Definition
Women Men
Characteristic NCEP No NCEP NCEP No NCEP
No. 193 556 117 498
Age, y 62.87.6 60.37.2 62.27.1 60.47.1
Current smoking, % 35 26 34 35
Former smoker, % 20 24 50 46
Systolic blood pressure, mm Hg 146.420.4 129.118.9 146.118.0 131.918.6
Diastolic blood pressure, mm Hg 84.810.7 79.49.9 87.39.1 82.510.0
Antihypertensive medication use, % 26.4 10.4 21 6.2
Total cholesterol, mmol/L 7.141.18 6.691.12 6.551.09 6.281.09
LDL cholesterol, mmol/L 4.981.12 4.571.06 4.521.02 4.411.01
Triglycerides, mmol/L 2.130.77 1.180.43 2.281.03 1.390.63
HDL cholesterol, mmol/L 1.200.26 1.590.34 1.000.24 1.260.31
Fasting glucose, mmol/L 5.630.58 5.220.47 5.860.59 5.420.45
Fasting insulin, pmol/L 102.754.6 74.138.4 103.245.8 84.462.1
BMI, kg/m2 29.03.3 25.63.2 28.03.0 25.32.5
Waist circumference, cm 938 839 1029 928
Waist-to-hip ratio 0.890.06 0.820.06 0.990.06 0.930.06
Framingham CHD risk score 9.76.4 4.33.9 21.37.0 15.17.1
Data are meanSD or percentage of subjects.
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Number of Risk Factors
The presence of 1 or 2 risk factors was also associated with
enhanced risk of CVD, particularly in women. The Figure
shows the age-adjusted hazard ratios of incident fatal and
nonfatal CVD according to the number of abnormalities with
the NCEP definitions. In these analyses, subjects with base-
line diabetes or history of CVD were included as separate
categories. Men with the metabolic syndrome according to
the NCEP definition had similar risk as men with diabetes but
less than men with prevalent CVD. Women with the meta-
bolic syndrome had lower risk than diabetic women, whose
risk approached that of those with prevalent CVD. When the
number of risk abnormalities was included as a linear
variable, the age-adjusted hazard ratio of fatal and nonfatal
CVD was 1.29 (1.11 to 1.50) per risk factor, and this was
identical for men and women. With increasing number of
abnormalities, the proportion of subjects with insulin 95.0
pmol/L (the upper quartile) increased, ranging from 10% in
men and 6% in women with no abnormalities to 50% with
4 or 5 abnormalities according to the NCEP definition.
Additional Analyses
When the HOMA estimate for insulin sensitivity was used
instead of fasting insulin for the WHO and EGIR definitions,
this increased the hazard ratios for all end points in men but not
in women (data not shown). The WHO and ACE definitions
originally also included elevated 2-hour glucose levels. Inclusion
of the 2-hour glucose levels barely affected the prevalence of the
syndrome, because most subjects with impaired glucose toler-
ance had several other abnormalities, and the hazard ratios did
not change markedly (data not shown). We then repeated
analyses without using the fasting glucose criterion. Importantly,
this had very little impact and did not differ between the 4
definitions. The prevalence of the syndrome according to the
NCEP definitions was reduced to 14% in men and 22% in
women. The hazard ratio of fatal and nonfatal CVD combined
was identical in men (1.91, 95% CI 1.27 to 2.87), and even
slightly higher in women (1.88, 95% CI 1.23 to 2.86).
Discussion
The NCEP definition was associated with an approximately
2-fold elevation in risk of fatal CVD in men and nonfatal
CVD in women, after adjustment for age only, compared with
patients without the NCEP criteria. For the WHO, EGIR, and
ACE definitions, the hazard ratios were somewhat lower.
Risk of CVD was strongly associated with the number of risk
factors. Although the number of risk factors was associated
with insulin level, definitions that required elevated fasting
insulin were no better predictors of CVD.
Previous Studies
Previous prospective studies reported associations between
metabolic syndrome definitions and risk of CVD that ranged
between 1.5 for fatal and nonfatal myocardial infarction or
stroke for the NCEP definition in high-risk subjects with
elevated cholesterol15 and 3.7 for fatal and nonfatal coronary
heart disease for the WHO definition in the general Italian
population.11 The present results are quite similar given that
these studies differ with respect to absolute risk of CVD,
definitions of the end points, gender, age, and cultural
aspects, including diet and physical activity. Furthermore,
because these studies used data already collected, the defini-
tions were mostly modified to accommodate the data. The
predictive value of the NCEP and WHO definitions was
compared previously.9,11,16 In the San Antonio Heart Study,
the NCEP definition was associated with a 2-fold higher risk
of CVD in subjects without diabetes or prevalent CVD,
whereas the WHO definition was not.16 In contrast, in 3
previous European studies, the WHO definition was associ-
ated with more than 2-fold risk.8,9,11 In 2 of these 3 studies,
the WHO definition included the presence of microalbumin-
uria, which was a strong risk factor in both studies.8,11 This
may explain the difference from the present study, in which
information on microalbuminuria was not used for the WHO
definition. In the combined data from 7 European cohort
studies reported by the Diabetes Epidemiology: Collaborative
analysis Of Diagnostic criteria in Europe (DECODE) study,
the hazard ratio of CVD mortality for the presence of 3 or
more abnormalities (of obesity, dyslipidemia, impaired glu-
cose regulation, or hypertension) was lower than with 2 or
more abnormalities, with hyperinsulinemia included as a
prerequisite.12 However, because several studies did not
measure waist circumference, obesity was defined as BMI
30 kg/m2. As also observed in the present study, a high
waist circumference is more strongly associated with CVD
than high BMI, and this may explain the difference, at least in
TABLE 3. Agreement () Between 4 Definitions of Metabolic Syndrome for Men and Women
Men
NCEP WHO EGIR ACE
NCEP    0.37 (0.29–0.45) 0.39 (0.30–0.48) 0.51 (0.44–0.57)
Women WHO 0.46 (0.37–0.52)    0.66 (0.59–0.72) 0.39 (0.32–0.47)
EGIR 0.44 (0.36–0.51) 0.74 (0.68–0.79)    0.28 (0.21–0.35)
ACE 0.78 (0.73–0.82) 0.41 (0.34–0.47) 0.36 (0.29–0.43)   
Agreement is shown as Cohen’s  (95% CI).
Numbers in the upper right corner are results for men; under the diagonal, for women.
The overlap between the definitions for men/women were: NCEP-WHO 75 %/79%, NCEP-EGIR 81%/81%,
NCEP-ACE 78%/90%, WHO-EGIR 87%/91%, WHO-ACE 72%/74%, and EGIR-ACE 68%/74%; a total of 9%/12% had
metabolic syndrome for all definitions, and 49%/56% did not have the metabolic syndrome with regard to any
definition.
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part. The observed gradually increasing risk with increasing
number of abnormalities is in line with the observations in
population studies in the United States13,14 and in subjects
with elevated cholesterol levels.10,15
Insulin Resistance or Obesity
The main purpose of the working definitions was standard-
ization. The working definitions of the WHO and subse-
quently the EGIR group in fact defined the “insulin resistance
syndrome.” These definitions are based on the premise that
insulin resistance is the causal factor. Therefore, insulin
levels, as a proxy for insulin resistance were included in the
definition. Insulin resistance is indeed associated with athero-
sclerosis, as measured by carotid intima thickness22 or coro-
nary calcification.23 Although fasting insulin is an accepted
proxy for insulin resistance in population studies, the agree-
ment between these parameters in the general population is
only moderate. In the EGIR database of 1308 nondiabetic
TABLE 4. CVD Risk Factors, Metabolic Syndrome Definitions, and Hazard Ratios of Fatal and Nonfatal CVD and All-Cause Mortality
% All-Cause Mortality Fatal CVD Nonfatal CVD Fatal and Nonfatal CVD
Men
No. of cases 94 39 107 132
Insulin 95.0 pmol/L 26.5 1.26 (0.82–1.94) 1.35 (0.70–2.61) 1.56 (1.05–2.32) 1.50 (1.04–2.14)
HOMA-IR 3.91 27.2 1.41 (0.93–2.15) 1.86 (0.98–3.51) 1.62 (1.09–2.40) 1.64 (1.15–2.34)
FPG 6.1 mmol/L 13.5 2.16 (1.36–3.45) 2.18 (1.06–4.48) 1.24 (0.74–2.09) 1.44 (0.93–2.25)
Waist 102 cm 15.3 2.01 (1.28–3.16) 2.25 (1.13–4.49) 1.74 (1.11–2.73) 1.81 (1.21–2.71)
Waist/hip ratio 0.9 67.3 1.10 (0.69–1.71) 1.52 (0.70–3.33) 1.37 (0.88–2.12) 1.49 (0.99–2.23)
Waist 94 cm 47.2 1.32 (0.87–2.00) 1.48 (0.77–2.85) 1.43 (0.97–2.11) 1.45 (1.02–2.06)
BMI 30 kg/m2 6.8 1.92 (1.02–3.61) 1.61 (0.57–4.53) 1.20 (0.58–2.46) 1.21 (0.64–2.31)
TG 1.7 mmol/L 32.4 0.99 (0.64–1.53) 0.99 (0.50–1.96) 1.24 (0.84–1.84) 1.08 (0.75–1.56)
TG 2 mmol/L 21.8 1.04 (0.60–1.80) 1.33 (0.65–2.72) 1.36 (0.88–2.09) 1.18 (0.79–1.76)
HDL 1.0 mmol/L 25.5 1.46 (0.95–2.24) 2.17 (1.15–4.09) 1.06 (0.69–1.64) 1.25 (0.86–1.82)
HDL 0.9 mmol/L 13.2 1.89 (1.14–3.14) 2.56 (1.25–5.25) 1.49 (0.90–2.48) 1.64 (1.05–2.56)
BP 130/85 mm Hg or HTN medication 65.2 2.08 (1.22–3.53) 3.07 (1.19–7.39) 1.60 (1.03–2.49) 1.82 (1.21–2.75)
BP 140/90 mm Hg or HTN medication 44.9 1.86 (1.21–2.89) 2.37 (1.19–4.74) 1.70 (1.15–2.50) 1.83 (1.29–2.60)
NCEP 19.0 1.98 (1.28–3.05) 2.25 (1.16–4.34) 1.88 (1.24–2.87) 1.91 (1.31–2.79)
WHO 32.4 1.29 (0.85–1.95) 1.45 (0.77–2.74) 1.43 (0.97–2.11) 1.45 (1.02–2.05)
EGIR 19.0 1.58 (1.01–2.47) 1.86 (0.95–3.64) 1.48 (0.96–2.29) 1.49 (1.01–2.21)
ACE 41.0 1.53 (1.02–2.29) 1.80 (0.96–3.40) 1.20 (0.82–1.76) 1.30 (0.92–1.83)
Women
No. of cases 70 26 75 95
Insulin 95.0 pmol/L 23.8 0.90 (0.53–1.53) 1.04 (0.45–2.40) 1.48 (0.92–2.40) 1.31 (0.85–2.02)
HOMA-IR 3.91 23.1 0.84 (0.49–1.44) 0.88 (0.37–2.11) 1.52 (0.94–2.46) 1.34 (0.87–2.07)
FPG 6.1 mmol/L 9.0 1.29 (0.69–2.44) 0.76 (0.22–2.57) 1.36 (0.71–2.61) 1.19 (0.65–2.15)
Waist 88 cm 38.7 1.13 (0.70–1.81) 0.57 (0.25–1.28) 1.68 (1.06–2.68) 1.31 (0.87–1.97)
Waist/hip ratio 0.85 50.0 1.15 (0.70–1.87) 0.69 (0.32–1.49) 1.37 (0.85–2.21) 1.20 (0.79–1.82)
Waist 80 cm 70.0 1.19 (0.67–2.12) 1.04 (0.41–2.60) 1.92 (1.03–3.57) 1.64 (0.96–2.78)
BMI 30 kg/m2 16.8 0.90 (0.49–1.65) 0.69 (0.24–2.01) 1.07 (0.60–1.89) 0.97 (0.58–1.69)
TG 1.7 mmol/L 26.0 1.22 (0.74–2.02) 2.27 (1.05–4.91) 1.83 (1.15–2.92) 1.92 (1.27–2.96)
TG 2.0 mmol/L 17.1 0.92 (0.50–1.72) 1.06 (0.40–2.81) 1.88 (1.14–3.12) 1.62 (1.02–2.58)
HDL 1.3 mmol/L 31.0 1.55 (0.96–2.49) 2.06 (0.95–4.46) 1.99 (1.26–3.15) 1.91 (1.27–2.87)
HDL 1.0 mmol/L 6.4 1.26 (0.51–3.12) 1.41 (0.33–5.98) 2.34 (1.16–4.64) 2.28 (1.22–4.28)
BP 130/85 mm Hg or HTN medication 62.2 0.76 (0.45–1.27) 0.87 (0.36–2.11) 1.52 (0.87–2.66) 1.31 (0.81–2.13)
BP 140/90 mm Hg or HTN medication 44.5 1.04 (0.64–1.68) 1.64 (0.71–3.82) 1.61 (0.99–2.61) 1.64 (1.06–2.53)
NCEP 25.8 1.18 (0.72–1.94) 0.76 (0.32–1.83) 2.05 (1.29–3.26) 1.68 (1.11–2.55)
WHO 26.3 1.01 (0.61–1.67) 0.98 (0.43–2.21) 1.48 (0.92–2.37) 1.31 (0.85–2.00)
EGIR 17.2 0.87 (0.49–1.55) 0.90 (0.36–2.26) 1.53 (0.92–2.56) 1.34 (0.85–2.14)
ACE 32.4 1.29 (0.80–2.07) 1.57 (0.72–3.42) 1.98 (1.25–3.15) 1.84 (1.22–2.78)
HOMA-IR indicates insulin resistance estimated by homeostasis model assessment; FPG, fasting plasma glucose; TG, triglycerides; BP, blood pressure; and HTN,
hypertension.
Data are baseline prevalence and age-adjusted hazard ratios (95% CI).
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subjects who had a euglycemic hyperinsulinemic clamp to
measure insulin sensitivity, the overlap between hyperinsu-
linemia and insulin resistance, defined as the upper 25% of
the distributions in 700 lean subjects, was only slightly more
than 50%.24 Furthermore, in studies with directly measured
insulin resistance in nondiabetic subjects, the NCEP defini-
tion and also the WHO definition of the metabolic syndrome
identified fewer than half of the insulin-resistant subjects.25,26
Finally, the causal relationship between insulin resistance and
CVD still needs to be established.
The other mechanism leading to the clustering of cardio-
vascular risk factors may be obesity per se. In a study of 314
nondiabetic volunteers who had a modified insulin suppres-
sion test to measure insulin sensitivity, BMI explained only
22% of the variation in insulin sensitivity.27 In this study and
in the EGIR data, the majority of obese people are not insulin
resistant.27,28 Furthermore, obesity leads to hyperinsulinemia
even after adjustment for insulin resistance,28 and it precedes
changes in components of the metabolic syndrome.29 In the
Insulin Resistance in Atherosclerosis Study (IRAS), a high
waist circumference was a better predictor of the incidence of
the metabolic syndrome than directly measured insulin resis-
tance.30 In line with this, in the present study, definitions that
included information on fasting insulin level were no better
predictors of CVD risk.
Strengths and Limitations of the Study
A number of limitations have to be taken into consideration.
We excluded subjects with missing information on nonfatal
disease because they did not give permission to access their
hospital records. To study the possibility of selection bias, we
repeated the analyses for mortality using the data from the
entire nondiabetic original Hoorn Study cohort, without
prevalent CVD, and estimates were almost identical (data not
shown). In the Hoorn Study, microalbuminuria has been
assessed only in a subsample and therefore could not be
studied in the present analyses. In the subsample, microalbu-
minuria had a strong association with CVD mortality,31 and it
may be speculated that addition of this information for the
WHO definition would increase its hazard ratio; however, in
general practice, microalbuminuria is not commonly
determined.
Not all the components of the metabolic syndrome ap-
peared to predict CVD morbidity and mortality equally
within both genders. Furthermore, gender-specific estimates
of hazard ratios for each metabolic syndrome definition but
without consideration of fasting plasma glucose levels were
in the same range for the end points analyzed as those
estimated with the full definitions. Possibly, the relative
weights and predictive properties of the various components
may vary by population studied. Previous studies in different
countries have shown widely varying estimates of the preva-
lences and associations with CVD.12,32 This has led to a
proposed different cutoff point for (abdominal) obesity for
subjects of Asian origin.32
This is the first study to prospectively study fatal and
nonfatal CVD separately in men and women in the general
population in relation to the metabolic syndrome. The number
of fatal CVD events was rather low in women, and the wide
CIs are still compatible with an increased risk of fatal CVD in
women. However, the number of cases of nonfatal CVD and
the number of cases of fatal and nonfatal CVD combined
TABLE 5. Metabolic Syndrome Definitions and Hazard Ratios of Risk of Fatal and Nonfatal CVD, With
Adjustment for Other CVD Factors and for 10-Year Framingham Risk*
Adjusted for: NCEP WHO EGIR ACE
Men
Age 1.91 (1.31–2.79) 1.45 (1.02–2.05) 1.49 (1.01–2.21) 1.30 (0.92–1.83)
Age, LDL cholesterol, current smoking 1.88 (1.28–2.76) 1.48 (1.04–2.12) 1.69 (1.13–2.54) 1.16 (0.82–1.65)
10-Year Framingham risk category 1.64 (1.11–2.44) 1.44 (1.01–2.04) 1.48 (0.99–2.19) 1.06 (0.74–1.53)
Women
Age 1.68 (1.11–2.55) 1.31 (0.85–2.00) 1.34 (0.87–2.14) 1.84 (1.22–2.78)
Age, LDL cholesterol, current smoking 1.44 (0.95–2.19) 1.32 (0.86–2.01) 1.33 (0.84–2.11) 1.52 (1.01–2.30)
10-Year Framingham risk category 1.17 (0.73–1.87) 1.31 (0.85–2.02) 1.21 (0.75–1.95) 1.31 (0.81–2.10)
Data are age-adjusted hazard ratios (95% CI).
*Framingham risk score and metabolic syndrome definitions both include information on HDL cholesterol and hypertension. There
was considerable variation in the presence of the metabolic syndrome over 10-year Framingham risk categories, and the models that
included both variables did not become unstable, as might be indicated by large changes in the estimate.
Number of metabolic syndrome abnormalities by NCEP defini-
tion, diabetes, and prevalent CVD and hazard ratios of 10-year
risk of fatal and nonfatal CVD. Bars show age-adjusted hazard
ratios for 0 (reference category), 1, 2, and 3 metabolic syn-
drome abnormalities by NCEP definition, baseline diabetes
(DM), and baseline prevalent CVD status.
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were sufficient to provide robust estimates in women and
men. The data suggest that associations with nonfatal CVD
generally were somewhat stronger in women than in men.
The presence of the metabolic syndrome is associated with a
similar increased risk of CVD in both genders, but in men,
cardiovascular events more often have a fatal outcome. This
may be important, because European guidelines for risk
stratification are based on risk of fatal CVD only.33 In
population studies in the United States, similar17 or even
higher16 risks of CVD mortality were reported for men and
women in the general population, but their analysis included
subjects with prevalent CVD and diabetes, and gender dif-
ferences in CVD risk are abolished by diabetes.34
Implications
After adjustment for the Framingham risk score, metabolic
syndrome definitions were no longer associated with risk of
CVD in women, and in men, the hazard ratios were reduced
to 1.5, as might be expected given the overlap in compo-
nents considered in these risk assessments. In AFCAPS/
TexCAPS (Air Force/Texas Coronary Atherosclerosis Pre-
vention Study) and 4S (Scandinavian Simvastatin Survival
Study), clinical trials of patients with prior congestive heart
disease and hypercholesterolemia or low HDL levels, strati-
fication by Framingham risk score did not abolish the
associations with the metabolic syndrome in placebo-treated
patients.15 The difference may be due to the much lower mean
CVD risk of the population-based participants of the Hoorn
Study, in which hypertension and low HDL, which are both
part of the Framingham risk score, were strongly and linearly
associated with risk of fatal and nonfatal CVD.
All metabolic syndrome definitions, which are meant to
facilitate decision making in clinical practice, are hampered
by the loss of information. The cutpoints that define abnor-
mality of the individual risk factor and the presence of the
syndrome ignore the gradual relationship with CVD risk of
the separate risk factors.
Conclusions
The results of the present study show that the metabolic
syndrome, however defined, is associated with increased risk
of fatal and nonfatal CVD, but the number of the constituent
factors present provides a more informative graded assess-
ment of risk in patients without diabetes or CVD.
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